The CRIPTOFAST trial demonstrates that ultra-early implantation of internal loop recorders significantly increases silent atrial fibrillation detection in cryptogenic stroke patients, particularly those with subtle left atrial anomalies, offering a targeted approach to secondary stroke prevention.